Thomas M Roberts
Overview
Explore the profile of Thomas M Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
9415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Csibi A, Lee G, Yoon S, Tong H, Ilter D, Elia I, et al.
Curr Biol
. 2024 Dec;
35(1):232.
PMID: 39675354
No abstract available.
2.
Huang K, Wang Y, Roberts T
Trends Biochem Sci
. 2024 Nov;
50(1):6-8.
PMID: 39551665
Recently developed KRAS inhibitors have delivered clinical benefits but their antitumor efficacy remains limited. A recent study by Klomp et al. reports an unprecedentedly comprehensive profiling of protein phosphorylation dependent...
3.
Berger R, Febbo P, Majumder P, Zhao J, Mukherjee S, Signoretti S, et al.
Cancer Res
. 2024 Aug;
84(15):2561.
PMID: 39086315
No abstract available.
4.
Sun B, Mason S, Wilson R, Hazard S, Wang Y, Fang R, et al.
Oncogene
. 2024 May;
43(25):1972.
PMID: 38811847
No abstract available.
5.
Wu Q, Yang R, Fan W, Wang L, Zhan J, Cao T, et al.
Adv Sci (Weinh)
. 2024 Apr;
11(22):e2310162.
PMID: 38602439
The inflammatory response is a key factor affecting tissue regeneration. Inspired by the immunomodulatory role of spermidine, an injectable double network hydrogel functionalized with spermidine (DN-SPD) is developed, where the...
6.
Gu H, Chen C, Hou Z, He X, Xie S, Ni J, et al.
Blood
. 2024 Jan;
143(19):1965-1979.
PMID: 38271660
Acute myeloid leukemia (AML) is an aggressive hematological malignancy originating from transformed hematopoietic stem or progenitor cells. AML prognosis remains poor owing to resistance and relapse driven by leukemia stem...
7.
Bergholz J, Wang Q, Wang Q, Ramseier M, Prakadan S, Wang W, et al.
Nature
. 2023 Apr;
617(7959):139-146.
PMID: 37076617
Loss of the PTEN tumour suppressor is one of the most common oncogenic drivers across all cancer types. PTEN is the major negative regulator of PI3K signalling. The PI3Kβ isoform...
8.
Ding L, Wang Q, Martincuks A, Kearns M, Jiang T, Lin Z, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36609487
Background: Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic....
9.
Manokaran C, Roberts T, Wang Y
Trends Pharmacol Sci
. 2022 Nov;
44(2):67-69.
PMID: 36414433
STING (stimulator of interferon genes) activation has considerable potential as a new strategy for cancer therapy, but clinical results have not been encouraging. Recent studies by Hong et al. and...
10.
Wang Q, Bergholz J, Ding L, Lin Z, Kabraji S, Hughes M, et al.
Nat Commun
. 2022 May;
13(1):3022.
PMID: 35641483
PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors with BRCA mutations. However, the impact of this class of inhibitors in patients with advanced BRCA-mutant breast...